Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention

Contributed by: PR Newswire

Tags

H-Lundbeck-A/S

More Like This

Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting

Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens

'LEQEMBI® Intravenous Infusion' approved for the treatment of Alzheimer's disease in Japan

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan